Skip to main
ICCM
ICCM logo

ICCM Stock Forecast & Price Target

ICCM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Icecure Medical Ltd is positioned for positively impacting its topline sales in the first half of 2026, largely due to anticipated FDA marketing authorization for its ProSense cryoablation system for breast cancer in 2025. The successful De Novo clearance and encouraging results from the ICE3 trial underscore the efficacy of their liquid nitrogen-based technology as a minimally invasive treatment alternative, which may further enhance market adoption. Additionally, a narrower net loss of $3.6 million per share, compared to earlier estimates, reflects improved financial stability and operational efficiency that could support future growth prospects.

Bears say

IceCure Medical reported a revenue of $725K for 1Q25, reflecting a 2% year-over-year decline, which aligns closely with projections but indicates stagnation in sales. The company faces challenges in achieving commercial success for its cryoablation systems due to limited market size and increasing competition, particularly highlighted by weak performance in the Asian market. Additionally, the presence of dilution risk further complicates the financial outlook, raising concerns among investors about the sustainability and growth potential of the company's revenue streams.

ICCM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Icecure Medical Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Icecure Medical Ltd (ICCM) Forecast

Analysts have given ICCM a Strong Buy based on their latest research and market trends.

According to 1 analysts, ICCM has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Icecure Medical Ltd (ICCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.